IMMUNEONCO-B (01541) announced its annual results for the period ending December 31, 2025. The company achieved revenue of 154 million yuan, representing an increase of 108.09% compared to the previous year. The loss attributable to the company's shareholders for the year narrowed by 30.8% to 219 million yuan. Gross profit reached 153 million yuan, up 106.59% year-on-year. Loss per share was 0.53 yuan.

The increase in revenue was primarily attributed to a recent payment received under an authorization and collaboration agreement signed with Axion Bio, Inc. in 2024. Research and development expenses remained relatively stable, totaling 322 million yuan for the year ending December 31, 2025, compared to 323 million yuan for the previous fiscal year. This stability was mainly due to an increase of 15.2 million yuan in clinical trial expenses, driven by the ongoing clinical development of IMM01 and IMM2510, and a rise of 10.4 million yuan in salaries and related benefits due to the expansion of the clinical team, aligning with the continued advancement and expansion of the drug pipeline. These increases were partially offset by a decrease of 9.8 million yuan in preclinical and CMC expenses, mainly due to reduced production and CDMO costs for IMM0306 and IMM2510, and a reduction of 10.8 million yuan in share-based payments, resulting from a decrease in the number of unvested restricted shares during the year.